vs
ASP Isotopes Inc.（ASPI）与CAPRICOR THERAPEUTICS, INC.（CAPR）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是CAPRICOR THERAPEUTICS, INC.的1.5倍（$16.7M vs $11.1M），ASP Isotopes Inc.同比增速更快（1295.7% vs -7.9%），CAPRICOR THERAPEUTICS, INC.自由现金流更多（$-15.3M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Capricor Therapeutics是一家处于临床阶段的生物技术企业，专注于研发及商业化细胞疗法、基因疗法等创新生物制剂，覆盖罕见病、心血管疾病、肌肉疾病等领域，主要面向美国市场，致力为治疗选择有限的患者填补未被满足的医疗需求。
ASPI vs CAPR — 直观对比
营收规模更大
ASPI
是对方的1.5倍
$11.1M
营收增速更快
ASPI
高出1303.6%
-7.9%
自由现金流更多
CAPR
多$32.1M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $11.1M |
| 净利润 | — | $-7.1M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -69.1% |
| 净利率 | — | -63.9% |
| 营收同比 | 1295.7% | -7.9% |
| 净利润同比 | -586.8% | -833.8% |
| 每股收益（稀释后） | — | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPICAPR
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q4 24 | — | $11.1M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | — | $4.9M | ||
| Q4 23 | — | $12.1M | ||
| Q3 23 | — | $6.2M |
净利润ASPICAPR
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q4 24 | — | $-7.1M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | $-11.0M | ||
| Q1 24 | — | $-9.8M | ||
| Q4 23 | — | $-762.1K | ||
| Q3 23 | — | $-6.4M |
毛利率ASPICAPR
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
营业利润率ASPICAPR
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q4 24 | — | -69.1% | ||
| Q3 24 | — | -575.2% | ||
| Q2 24 | — | -291.9% | ||
| Q1 24 | — | -209.2% | ||
| Q4 23 | — | -10.6% | ||
| Q3 23 | — | -111.0% |
净利率ASPICAPR
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q4 24 | — | -63.9% | ||
| Q3 24 | — | -555.2% | ||
| Q2 24 | — | -277.0% | ||
| Q1 24 | — | -199.6% | ||
| Q4 23 | — | -6.3% | ||
| Q3 23 | — | -103.3% |
每股收益（稀释后）ASPICAPR
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.38 | ||
| Q2 24 | — | $-0.35 | ||
| Q1 24 | — | $-0.31 | ||
| Q4 23 | — | $0.02 | ||
| Q3 23 | — | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $151.5M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $145.5M |
| 总资产 | $498.0M | $170.5M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPICAPR
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q4 24 | — | $151.5M | ||
| Q3 24 | — | $85.0M | ||
| Q2 24 | — | $29.5M | ||
| Q1 24 | — | $39.9M | ||
| Q4 23 | — | $39.5M | ||
| Q3 23 | — | $28.5M |
总债务ASPICAPR
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
股东权益ASPICAPR
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q4 24 | — | $145.5M | ||
| Q3 24 | — | $68.3M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $18.4M | ||
| Q4 23 | — | $22.6M | ||
| Q3 23 | — | $-1.8M |
总资产ASPICAPR
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q4 24 | — | $170.5M | ||
| Q3 24 | — | $93.0M | ||
| Q2 24 | — | $38.3M | ||
| Q1 24 | — | $49.4M | ||
| Q4 23 | — | $58.7M | ||
| Q3 23 | — | $37.2M |
负债/权益比ASPICAPR
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-14.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-15.3M |
| 自由现金流率自由现金流/营收 | -284.7% | -137.3% |
| 资本支出强度资本支出/营收 | 57.9% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-41.2M |
8季度趋势，按日历期对齐
经营现金流ASPICAPR
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q4 24 | — | $-14.8M | ||
| Q3 24 | — | $-11.6M | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-1.3M | ||
| Q4 23 | — | $-11.6M | ||
| Q3 23 | — | $-8.8M |
自由现金流ASPICAPR
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q4 24 | — | $-15.3M | ||
| Q3 24 | — | $-11.7M | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-1.9M | ||
| Q4 23 | — | $-12.2M | ||
| Q3 23 | — | $-9.1M |
自由现金流率ASPICAPR
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q4 24 | — | -137.3% | ||
| Q3 24 | — | -515.2% | ||
| Q2 24 | — | -310.9% | ||
| Q1 24 | — | -38.3% | ||
| Q4 23 | — | -100.5% | ||
| Q3 23 | — | -146.5% |
资本支出强度ASPICAPR
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 12.4% | ||
| Q4 23 | — | 4.6% | ||
| Q3 23 | — | 4.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
